Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.

Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. doi: 10.1038/s41391-018-0043-z. Epub 2018 Jun 1.

2.

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L, Kohli M.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):431-437. doi: 10.1038/s41391-018-0046-9. Epub 2018 Jun 1.

3.

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA.

Ann Oncol. 2018 Oct 1;29(10):2150. doi: 10.1093/annonc/mdx811. No abstract available.

4.

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.

Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M.

Int J Mol Sci. 2017 Nov 3;18(11). pii: E2326. doi: 10.3390/ijms18112326.

5.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.

Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M.

Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689.

6.

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L.

Clin Pharmacol Ther. 2018 Jul;104(1):201-210. doi: 10.1002/cpt.907. Epub 2017 Nov 22.

7.

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP.

Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14.

8.

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM.

Clin Cancer Res. 2017 Aug 15;23(16):4704-4715. doi: 10.1158/1078-0432.CCR-17-0017. Epub 2017 May 4.

9.

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.

Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M.

Int J Mol Sci. 2016 Jul 9;17(7). pii: E1097. doi: 10.3390/ijms17071097.

10.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

11.

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.

12.

Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.

Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJ.

Breast Cancer Res. 2012 May 11;14(3):R75.

13.

Germline predictors of androgen deprivation therapy response in advanced prostate cancer.

Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR.

Mayo Clin Proc. 2012 Mar;87(3):240-6. doi: 10.1016/j.mayocp.2011.09.009.

14.

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B.

J Natl Cancer Inst. 2012 Jan 18;104(2):159-62. doi: 10.1093/jnci/djr490. Epub 2011 Dec 2.

15.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB.

J Clin Oncol. 2010 Oct 1;28(28):4307-15. doi: 10.1200/JCO.2009.26.2154. Epub 2010 Aug 9.

16.

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.

Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC.

Ann Oncol. 2010 Feb;21(2):269-74. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9.

17.

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA.

Ann Oncol. 2010 Mar;21(3):493-7. doi: 10.1093/annonc/mdp328. Epub 2009 Jul 22. Erratum in: Ann Oncol. 2018 Oct 1;29(10):2150.

18.

Identification and localization of myosin superfamily members in fish retina and retinal pigmented epithelium.

Lin-Jones J, Sohlberg L, Dosé A, Breckler J, Hillman DW, Burnside B.

J Comp Neurol. 2009 Mar 10;513(2):209-23. doi: 10.1002/cne.21958.

19.

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA.

J Clin Oncol. 2009 Jan 1;27(1):11-5. doi: 10.1200/JCO.2007.15.5242. Epub 2008 Dec 1.

20.

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G.

Clin Cancer Res. 2008 Dec 1;14(23):7940-6. doi: 10.1158/1078-0432.CCR-08-0221.

21.

Estimated limits of IMRT dose escalation using varied planning target volume margins.

Goulet CC, Herman MG, Hillman DW, Davis BJ.

Phys Med Biol. 2008 Jul 21;53(14):3777-88. doi: 10.1088/0031-9155/53/14/005. Epub 2008 Jun 23.

PMID:
18574311
22.

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

Inwards DJ, Fishkin PA, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Veeder MH, Witzig TE.

Cancer. 2008 Jul 1;113(1):108-16. doi: 10.1002/cncr.23537.

23.

Prediction of radial distance of extraprostatic extension from pretherapy factors.

Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, Mynderse LA, Choo R, Davis BJ.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):411-8.

PMID:
17869661
24.

Permanent prostate brachytherapy: pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy.

Sengupta S, Davis BJ, Mynderse LA, Sebo TJ, Cheville JC, Lohse CM, Hillman DW, Haddock MG, Wilson TM.

Urology. 2006 Oct;68(4):810-4.

PMID:
17070358
25.

A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.

Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA.

Ann Oncol. 2006 Feb;17(2):226-31. Epub 2005 Nov 22.

PMID:
16303865
26.

Benign breast disease and the risk of breast cancer.

Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW.

N Engl J Med. 2005 Jul 21;353(3):229-37.

27.

Phase II trial of dolastatin-10 in patients with advanced breast cancer.

Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR.

Invest New Drugs. 2005 Jun;23(3):257-61.

PMID:
15868383
28.

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.

Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ.

Cancer Res. 2005 Apr 15;65(8):3059-62.

29.

Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.

Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN.

Am J Clin Oncol. 2005 Apr;28(2):195-200.

PMID:
15803016
30.

Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression.

Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Hillman DW, Herman MG, King BF.

Cancer J. 2004 Nov-Dec;10(6):343-8.

PMID:
15701265
31.

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.

Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR.

J Clin Oncol. 2004 Jul 15;22(14):2849-55.

PMID:
15254052
32.

Long-term follow-up of women with ovarian cancer after positive second-look laparotomy.

Dowdy SC, Constantinou CL, Hartmann LC, Keeney GL, Suman VJ, Hillman DW, Podratz KC.

Gynecol Oncol. 2003 Dec;91(3):563-8.

PMID:
14675677
33.
34.

DSMB case study: decision making when a similar clinical trial is stopped early.

Hillman DW, Louis TA.

Control Clin Trials. 2003 Feb;24(1):85-91.

PMID:
12559646
35.

The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.

Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H.

Cancer. 2002 Aug 1;95(3):513-9.

36.

Phase II trial of KW2189 in patients with advanced malignant melanoma.

Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Leitch JM, Creagan ET.

Am J Clin Oncol. 2002 Jun;25(3):308-12.

PMID:
12040295
37.

A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.

Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1175-85.

38.

Rapid reporting and review of an increased incidence of a known adverse event.

Sargent DJ, Goldberg RM, Mahoney MR, Hillman DW, McKeough T, Hamilton SF, Darcy JM, Anderson VL, Krook JE, O'Connell MJ.

J Natl Cancer Inst. 2000 Jun 21;92(12):1011-3. No abstract available.

PMID:
10861314
39.

Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.

Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE.

J Urol. 2000 Mar;163(3):845-50.

PMID:
10687990
40.

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.

Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, Hatfield AK, Mailliard JA, Nair S, Kardinal CG, Ingle JN.

Cancer. 2000 Jan 1;88(1):124-31.

PMID:
10618614
41.

The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy.

Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG.

Cancer. 1999 Jun 15;85(12):2630-7.

PMID:
10375112
42.

A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.

Brosgart CL, Louis TA, Hillman DW, Craig CP, Alston B, Fisher E, Abrams DI, Luskin-Hawk RL, Sampson JH, Ward DJ, Thompson MA, Torres RA.

AIDS. 1998 Feb 12;12(3):269-77.

PMID:
9517989
43.
44.

In search of an elusive stomach.

Hillman DW.

Radiol Technol. 1994 Nov-Dec;66(2):129-30. No abstract available.

PMID:
7855237
45.

Exemplary data: sample size and power in the design of event-time clinical trials.

Goldman AI, Hillman DW.

Control Clin Trials. 1992 Aug;13(4):256-71.

PMID:
1330432
46.

Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury.

Moody DE, Loury DN, Hammock BD, Ruebner BH, Cullen JM, Hillman JH, Hillman DW, Rao MS, London WT, Hann HW, et al.

Cancer Epidemiol Biomarkers Prev. 1992 Jul-Aug;1(5):395-403.

48.

Design for a fast fluorescence laser scanning microscope.

Shack RV, Bartels PH, Buchroeder RA, Shoemaker RL, Hillman DW, Vukobratovich D.

Anal Quant Cytol Histol. 1987 Dec;9(6):509-20.

PMID:
3435628
49.

An ultrafast laser scanner microscope for digital image analysis.

Shoemaker RL, Bartels PH, Hillman DW, Jonas J, Kessler D, Shack RV, Vukobratovich D.

IEEE Trans Biomed Eng. 1982 Feb;29(2):82-91. No abstract available.

PMID:
7056561
50.

Ultrafast laser scanner microscope: design and construction.

Bartels PH, Buchroeder RA, Hillman DW, Jonas JA, Kessler D, Shoemaker RM, Shack RV, Towner D, Vukobratovich D.

Anal Quant Cytol. 1981 Mar;3(1):55-66.

PMID:
7235391

Supplemental Content

Loading ...
Support Center